Ferric Carboxymaltose [Ferinject]
Tubular Breast Cancer Stage II
GBG Forschungs GmbHPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tubular Breast Cancer Stage II cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin GBG Forschungs GmbH | Phase 3 | BBB |
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER GBG Forschungs GmbH | Phase 3 | BB |
TRASTUZUMAB GBG Forschungs GmbH | Phase 3 | BB |
Epirubicin GBG Forschungs GmbH | Phase 3 | BB |
Cyclophosphamide GBG Forschungs GmbH | Phase 3 | BB |
Inno-206 GBG Forschungs GmbH | Phase 3 | BB |
FERRIC CATION GBG Forschungs GmbH | Phase 3 | BB |
Denosumab GBG Forschungs GmbH | Phase 2 | B |
Same molecule, other indications
Ferric Carboxymaltose [Ferinject] is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →